PL3865155T3 - Sposób miejscowo-specyficznego modyfikowania przeciwciała - Google Patents
Sposób miejscowo-specyficznego modyfikowania przeciwciałaInfo
- Publication number
- PL3865155T3 PL3865155T3 PL20305138.8T PL20305138T PL3865155T3 PL 3865155 T3 PL3865155 T3 PL 3865155T3 PL 20305138 T PL20305138 T PL 20305138T PL 3865155 T3 PL3865155 T3 PL 3865155T3
- Authority
- PL
- Poland
- Prior art keywords
- antibody
- site
- specific modification
- modification
- specific
- Prior art date
Links
- 238000000034 method Methods 0.000 title 1
- 230000004048 modification Effects 0.000 title 1
- 238000012986 modification Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
- A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1027—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against receptors, cell-surface antigens or cell-surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1051—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from breast, e.g. the antibody being herceptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
- A61K51/1069—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants the tumor cell being from blood cells, e.g. the cancer being a myeloma
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20305138.8A EP3865155B1 (en) | 2020-02-13 | 2020-02-13 | Process for site-specific modification of an antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3865155T3 true PL3865155T3 (pl) | 2023-01-30 |
Family
ID=69740312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL20305138.8T PL3865155T3 (pl) | 2020-02-13 | 2020-02-13 | Sposób miejscowo-specyficznego modyfikowania przeciwciała |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20230120220A1 (pl) |
| EP (1) | EP3865155B1 (pl) |
| JP (1) | JP7671768B2 (pl) |
| KR (1) | KR20220140803A (pl) |
| CN (1) | CN115175708B (pl) |
| AU (1) | AU2021220275A1 (pl) |
| BR (1) | BR112022015765A2 (pl) |
| CA (1) | CA3166956A1 (pl) |
| ES (1) | ES2934984T3 (pl) |
| FI (1) | FI3865155T3 (pl) |
| IL (1) | IL295163A (pl) |
| PL (1) | PL3865155T3 (pl) |
| PT (1) | PT3865155T (pl) |
| WO (1) | WO2021160724A1 (pl) |
| ZA (1) | ZA202208650B (pl) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1738640A (zh) * | 2002-11-18 | 2006-02-22 | 马克西根公司 | 干扰素－α多肽和偶联物 |
| EP3179252B1 (en) * | 2004-07-30 | 2018-11-14 | Promega Corporation | Covalent tethering of functional groups to proteins and substrates therefor |
| CA2637988A1 (en) * | 2006-02-10 | 2007-11-29 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| JP5677972B2 (ja) * | 2008-11-18 | 2015-02-25 | メリマック ファーマシューティカルズ インコーポレーティッド | ヒト血清アルブミンリンカーおよびそのコンジュゲート |
| WO2012142659A1 (en) * | 2011-04-19 | 2012-10-26 | Baker Idi Heart And Diabetes Institute Holdings Limited | Site-selective modification of proteins |
| IL289918B2 (en) * | 2013-03-11 | 2025-07-01 | Genzyme Corp | Site-specific antibody-drug conjugation through glycoengineering |
| DK3261681T3 (da) * | 2015-02-26 | 2020-04-27 | Sciencons AS | Radiofarmaceutiske opløsninger med fordelagtige egenskaber |
| CA2994741A1 (en) | 2015-08-07 | 2017-02-16 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
| EP3272864A1 (en) * | 2016-07-20 | 2018-01-24 | Paul Scherrer Institut | Solid-phase immobilization of microbial transglutaminase mtg on microbeads for protein conjugation |
| NZ762376A (en) * | 2017-09-19 | 2022-08-26 | Scherrer Inst Paul | Transglutaminase conjugation method and linker |
| CA3094719A1 (en) * | 2018-04-05 | 2019-10-10 | Tarveda Therapeutics, Inc. | Hsp90-targeting conjugates and formulations thereof |
-
2020
- 2020-02-13 PL PL20305138.8T patent/PL3865155T3/pl unknown
- 2020-02-13 PT PT203051388T patent/PT3865155T/pt unknown
- 2020-02-13 FI FIEP20305138.8T patent/FI3865155T3/fi active
- 2020-02-13 EP EP20305138.8A patent/EP3865155B1/en active Active
- 2020-02-13 ES ES20305138T patent/ES2934984T3/es active Active
-
2021
- 2021-02-11 WO PCT/EP2021/053297 patent/WO2021160724A1/en not_active Ceased
- 2021-02-11 AU AU2021220275A patent/AU2021220275A1/en active Pending
- 2021-02-11 US US17/798,879 patent/US20230120220A1/en active Pending
- 2021-02-11 CA CA3166956A patent/CA3166956A1/en active Pending
- 2021-02-11 KR KR1020227031504A patent/KR20220140803A/ko active Pending
- 2021-02-11 JP JP2022549175A patent/JP7671768B2/ja active Active
- 2021-02-11 CN CN202180014136.6A patent/CN115175708B/zh active Active
- 2021-02-11 BR BR112022015765A patent/BR112022015765A2/pt unknown
- 2021-02-11 IL IL295163A patent/IL295163A/en unknown
-
2022
- 2022-08-02 ZA ZA2022/08650A patent/ZA202208650B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3166956A1 (en) | 2021-08-19 |
| ES2934984T3 (es) | 2023-02-28 |
| KR20220140803A (ko) | 2022-10-18 |
| PT3865155T (pt) | 2023-01-02 |
| CN115175708B (zh) | 2023-07-18 |
| FI3865155T3 (fi) | 2023-01-13 |
| IL295163A (en) | 2022-09-01 |
| WO2021160724A1 (en) | 2021-08-19 |
| JP7671768B2 (ja) | 2025-05-02 |
| EP3865155B1 (en) | 2022-11-30 |
| JP2023513804A (ja) | 2023-04-03 |
| EP3865155A1 (en) | 2021-08-18 |
| ZA202208650B (en) | 2023-04-26 |
| US20230120220A1 (en) | 2023-04-20 |
| CN115175708A (zh) | 2022-10-11 |
| BR112022015765A2 (pt) | 2022-10-11 |
| AU2021220275A1 (en) | 2022-09-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ714079A (en) | Purification process for monoclonal antibodies | |
| EP3939453A4 (en) | PREHEATING METHOD FOR AN ELECTRONIC CIGARETTE | |
| GB201911685D0 (en) | Process for purifying monoclonal antibodies | |
| IL292210A (en) | An efficient process for the synthesis of 2-amino-5-chloro-n,3-dimethylbenzamide | |
| IL285768A (en) | Methods for use in generating organoids for high-throughput drug screening | |
| GB202306569D0 (en) | Process for cracking ammonia | |
| IL279528A (en) | A method for producing a controlled mixture of two or more different antibodies | |
| EP3774285C0 (en) | METHOD AND APPARATUS FOR FORMING AN OBJECT USING ADDITIVE MANUFACTURING | |
| ZA202200018B (en) | Method for synthesizing m-methoxyphenol | |
| ZA201908294B (en) | Method for preparing transmission electron microscope sample of powder particles | |
| SG11202108320PA (en) | Method of selecting for antibodies | |
| ZA202208650B (en) | Process for site-specific modification of an antibody | |
| EP3924985C0 (de) | Spule und verfahren zur herstellung der spule | |
| IL308393A (en) | Antibodies for the treatment of alpha-synuclein diseases | |
| GB202008860D0 (en) | BTLA antibodies | |
| HUP2100414A1 (hu) | Eljárás bioadszorbens anyag elõállítására | |
| HUE067878T2 (hu) | Eljárás alkilamidotiazolok gyártásához | |
| EP4291568A4 (en) | METHODS FOR PURIFICATION OF MONOCLONAL ANTIBODIES | |
| GB201812056D0 (en) | Method of an apparatus for producing nanomaterials | |
| IL316018A (en) | IMPROVED PROCESS FOR THE MANUFACTURE OF OSIMERTINIB | |
| ZA202107520B (en) | Method for producing carbon-based products from secondary raw materials containing ph regulators | |
| GB201914819D0 (en) | Method of selecting for antibodies | |
| GB201913333D0 (en) | Method of selecting for antibodies | |
| GB201903270D0 (en) | Method of selecting for antibodies | |
| GB201903233D0 (en) | Method of selecting for antibodies |